New anthrax vaccine shows promise in phase 2 trial

NCT ID NCT05997264

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Biomedical Advanced Research and Development Authority Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times

Summary

This study tests an anthrax vaccine called AV7909 in 220 healthy adults aged 18 to 65. Researchers want to see how safe it is and how well it triggers the immune system, using two different dose levels and schedules, including booster shots at 6 and 12 months. The goal is to find the best way to protect people against anthrax infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTHRAX are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Accellacare Knoxville

Jefferson City, Tennessee, 37760, United States
Accellacare Knoxville

Knoxville, Tennessee, 37912, United States
Accellacare Knoxville

Knoxville, Tennessee, 37938, United States
Accellacare of Hickory

Hickory, North Carolina, 28601, United States
Accellacare of Piedmont

Statesville, North Carolina, 28625, United States
Accellacare of Salisbury

Salisbury, North Carolina, 28144, United States
Accellacare of Winston-Salem

Winston-Salem, North Carolina, 27103, United States

Conditions

Explore the condition pages connected to this study.

ANTHRAX